文献速递神经肿瘤神经重症

靶向线粒体蛋白酶ClpP治疗H3 K27变异型弥漫性中线胶质瘤的现状综述

A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered.
PubMed 文献 · Neuro Oncol · 2024-01-01

弥漫性中线胶质瘤(DMG)是致死性儿童脑肿瘤,H3K27变异为其特征。本文综述dordaviprone安全性,探讨其临床前作用机制,确定线粒体蛋白酶ClpP为反应生物标志物,并讨论其他ClpP激动剂及联合策略。

要点

  • DMG为儿童癌症相关死亡首要原因,以H3K27全局低甲基化为特征。
  • 一例22岁丘脑DMG患者对dordaviprone出现显著临床和影像学反应,H3野生型肿瘤无反应。
  • 线粒体蛋白酶ClpP被确定为dordaviprone反应的生物标志物。

核心结论

  • dordaviprone在H3 K27变异型DMG中显示临床获益,ClpP为反应生物标志物,其他ClpP激动剂及联合策略值得进一步研究。

研究设计与样本

  • 综述,总结dordaviprone安全性、临床前作用机制、其他ClpP激动剂及联合策略。

主要发现

  • 成人进展性HGG试验中,一例22岁丘脑DMG(H3 K27变异)患者对dordaviprone出现显著临床和影像学反应,而H3野生型肿瘤患者无反应。
  • dordaviprone的临床前作用机制研究确定线粒体蛋白酶ClpP为反应生物标志物,但反应生物标志物尚未解决。
  • 其他ClpP激动剂及联合策略具有免疫调节效应,提示肿瘤微环境在DMG患者反应中可能起作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse midline gliomas (DMGs) are devastating pediatric brain tumors recognized as the leading cause of cancer-related death in children. DMGs are high-grade gliomas (HGGs) diagnosed along the brain's midline. Euchromatin is the hallmark feature of DMG, caused by global hypomethylation of H3K27 either through point mutations in histone H3 genes (H3K27M), or by overexpression of the enhancer of zeste homolog inhibitory protein. In a clinical trial for adults with progressive HGGs, a 22-year-old patient with a thalamic DMG, H3 K27-altered, showed a remarkable clinical and radiological response to dordaviprone (ONC201). This response in an H3 K27-altered HGG patient, coupled with the lack of response of patients harboring wildtype-H3 tumors, has increased the clinical interest in dordaviprone for the treatment of DMG. Additional reports of clinical benefit have emerged, but research defining mechanisms of action (MOA) fall behind dordaviprone's clinical use, with biomarkers of response unresolved. Here, we summarize dordaviprone's safety, interrogate its preclinical MOA identifying the mitochondrial protease "ClpP" as a biomarker of response, and discuss other ClpP agonists, expanding the arsenal of potential weapons in the fight against DMG. Finally, we discuss combination strategies including ClpP agonists, and their immunomodulatory effects suggestive of a role for the tumor microenvironment in DMG patient response.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Jackson ER, Persson ML, Fish CJ, et al. A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered. Neuro Oncol. 2024. PMID: 37589388. doi:10.1093/neuonc/noad144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。